Cargando…

Performance of human papillomavirus E6/E7 mRNA assay for primary cervical cancer screening and triage: Population-based screening in China

OBJECTIVE: Cervical cancer screening is very important in the prevention and treatment of cervical cancer. In China, the cervical screening strategy needs to be improved. To explore a suitable cervical screening strategy in China, we evaluated the performance of the human papillomavirus (HPV) E6/E7...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jing, Yang, Di, Cui, Xiaoli, Liu, Guangcong, Cui, Zhumei, Wang, Chunyan, Piao, Haozhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465014/
https://www.ncbi.nlm.nih.gov/pubmed/36105144
http://dx.doi.org/10.3389/fcimb.2022.935071
_version_ 1784787698674827264
author Zhang, Jing
Yang, Di
Cui, Xiaoli
Liu, Guangcong
Cui, Zhumei
Wang, Chunyan
Piao, Haozhe
author_facet Zhang, Jing
Yang, Di
Cui, Xiaoli
Liu, Guangcong
Cui, Zhumei
Wang, Chunyan
Piao, Haozhe
author_sort Zhang, Jing
collection PubMed
description OBJECTIVE: Cervical cancer screening is very important in the prevention and treatment of cervical cancer. In China, the cervical screening strategy needs to be improved. To explore a suitable cervical screening strategy in China, we evaluated the performance of the human papillomavirus (HPV) E6/E7 mRNA (Aptima HPV (AHPV)) assay in primary screening and different triage strategies for women undergoing routine cervical screening. METHODS: A total of 10,002 women aged 35 to 65 years of age were recruited in Liaoning Province and Qingdao City, China. Specimens were tested by liquid-based cytology (LBC) and the AHPV assay, and women who tested positive on any test were referred for colposcopy. Genotyping was performed on all high-risk HPV (HR-HPV)-positive samples. Test characteristics were calculated based on histological review. RESULTS: We identified 109 women with high-grade squamous intraepithelial lesion or worse (HSIL+), including six with cervical cancer. The sensitivity of AHPV was clearly higher than that of LBC (92.7 [95% CI: 87.2, 97.2] vs. 67.9 [95% CI: 59.6, 76.1], p < 0.001). The specificity of AHPV was 93.0 (95% CI: 92.5, 93.5), which was lower than that of LBC (95.2 [95% CI: 94.8, 95.6], p < 0.001). There was no statistical difference between the positive predictive value of AHPV and LBC (13.5 [95% CI: 11.2, 16.2] vs. 14.3 [95% CI: 11.4, 17.6], p = 0.695). The difference of area under the curve (AUC) values between the AHPV test (0.928 [95% CI: 0.904, 0.953]) and LBC test (0.815 [95% CI: 0.771, 0.860]) in detecting HSIL+ was statistically significant (p < 0.001). Finally, among the three triage strategies, both the sensitivity (73.4 [95% CI: 65.1, 81.7]) and AUC (0.851 [95% CI: 0.809, 0.892]) of AHPV genotyping with reflex LBC triage were the greatest. CONCLUSION: In summary, the AHPV assay is both specific and sensitive for detecting HSIL+ and may be suitable for use in primary cervical cancer screening in China. AHPV genotyping with reflex LBC triage may be a feasible triage strategy.
format Online
Article
Text
id pubmed-9465014
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94650142022-09-13 Performance of human papillomavirus E6/E7 mRNA assay for primary cervical cancer screening and triage: Population-based screening in China Zhang, Jing Yang, Di Cui, Xiaoli Liu, Guangcong Cui, Zhumei Wang, Chunyan Piao, Haozhe Front Cell Infect Microbiol Cellular and Infection Microbiology OBJECTIVE: Cervical cancer screening is very important in the prevention and treatment of cervical cancer. In China, the cervical screening strategy needs to be improved. To explore a suitable cervical screening strategy in China, we evaluated the performance of the human papillomavirus (HPV) E6/E7 mRNA (Aptima HPV (AHPV)) assay in primary screening and different triage strategies for women undergoing routine cervical screening. METHODS: A total of 10,002 women aged 35 to 65 years of age were recruited in Liaoning Province and Qingdao City, China. Specimens were tested by liquid-based cytology (LBC) and the AHPV assay, and women who tested positive on any test were referred for colposcopy. Genotyping was performed on all high-risk HPV (HR-HPV)-positive samples. Test characteristics were calculated based on histological review. RESULTS: We identified 109 women with high-grade squamous intraepithelial lesion or worse (HSIL+), including six with cervical cancer. The sensitivity of AHPV was clearly higher than that of LBC (92.7 [95% CI: 87.2, 97.2] vs. 67.9 [95% CI: 59.6, 76.1], p < 0.001). The specificity of AHPV was 93.0 (95% CI: 92.5, 93.5), which was lower than that of LBC (95.2 [95% CI: 94.8, 95.6], p < 0.001). There was no statistical difference between the positive predictive value of AHPV and LBC (13.5 [95% CI: 11.2, 16.2] vs. 14.3 [95% CI: 11.4, 17.6], p = 0.695). The difference of area under the curve (AUC) values between the AHPV test (0.928 [95% CI: 0.904, 0.953]) and LBC test (0.815 [95% CI: 0.771, 0.860]) in detecting HSIL+ was statistically significant (p < 0.001). Finally, among the three triage strategies, both the sensitivity (73.4 [95% CI: 65.1, 81.7]) and AUC (0.851 [95% CI: 0.809, 0.892]) of AHPV genotyping with reflex LBC triage were the greatest. CONCLUSION: In summary, the AHPV assay is both specific and sensitive for detecting HSIL+ and may be suitable for use in primary cervical cancer screening in China. AHPV genotyping with reflex LBC triage may be a feasible triage strategy. Frontiers Media S.A. 2022-08-29 /pmc/articles/PMC9465014/ /pubmed/36105144 http://dx.doi.org/10.3389/fcimb.2022.935071 Text en Copyright © 2022 Zhang, Yang, Cui, Liu, Cui, Wang and Piao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Zhang, Jing
Yang, Di
Cui, Xiaoli
Liu, Guangcong
Cui, Zhumei
Wang, Chunyan
Piao, Haozhe
Performance of human papillomavirus E6/E7 mRNA assay for primary cervical cancer screening and triage: Population-based screening in China
title Performance of human papillomavirus E6/E7 mRNA assay for primary cervical cancer screening and triage: Population-based screening in China
title_full Performance of human papillomavirus E6/E7 mRNA assay for primary cervical cancer screening and triage: Population-based screening in China
title_fullStr Performance of human papillomavirus E6/E7 mRNA assay for primary cervical cancer screening and triage: Population-based screening in China
title_full_unstemmed Performance of human papillomavirus E6/E7 mRNA assay for primary cervical cancer screening and triage: Population-based screening in China
title_short Performance of human papillomavirus E6/E7 mRNA assay for primary cervical cancer screening and triage: Population-based screening in China
title_sort performance of human papillomavirus e6/e7 mrna assay for primary cervical cancer screening and triage: population-based screening in china
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465014/
https://www.ncbi.nlm.nih.gov/pubmed/36105144
http://dx.doi.org/10.3389/fcimb.2022.935071
work_keys_str_mv AT zhangjing performanceofhumanpapillomaviruse6e7mrnaassayforprimarycervicalcancerscreeningandtriagepopulationbasedscreeninginchina
AT yangdi performanceofhumanpapillomaviruse6e7mrnaassayforprimarycervicalcancerscreeningandtriagepopulationbasedscreeninginchina
AT cuixiaoli performanceofhumanpapillomaviruse6e7mrnaassayforprimarycervicalcancerscreeningandtriagepopulationbasedscreeninginchina
AT liuguangcong performanceofhumanpapillomaviruse6e7mrnaassayforprimarycervicalcancerscreeningandtriagepopulationbasedscreeninginchina
AT cuizhumei performanceofhumanpapillomaviruse6e7mrnaassayforprimarycervicalcancerscreeningandtriagepopulationbasedscreeninginchina
AT wangchunyan performanceofhumanpapillomaviruse6e7mrnaassayforprimarycervicalcancerscreeningandtriagepopulationbasedscreeninginchina
AT piaohaozhe performanceofhumanpapillomaviruse6e7mrnaassayforprimarycervicalcancerscreeningandtriagepopulationbasedscreeninginchina